A Phase 3 interventional study of Eculizumab and Placebo in Guillain-Barre Syndrome, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 22 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG) scale as progressively deteriorating FG3 or FG4/FG5 within 2 weeks from onset of weakness due to GBS.
This study will be conducted only at sites in Japan.
Eligible participants will be randomized to receive intravenous (IV) infusion of eculizumab or placebo at a 2:1 ratio. All participants will be on concomitant IV immunoglobulin G (Ig) therapy as per standard of care.
98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.
This study's enrollment of 57 is above the median of 50 across 44 interventional studies indexed under Guillain-Barre Syndrome.
Browse Guillain-Barre Syndrome studies →Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eculizumab.
Biological: Eculizumab
Participants will receive placebo.
Drug: Placebo
Eculizumab will be administered via IV infusion once a week for 4 weeks.
Also known as: Soliris
Placebo will be administered via IV infusion once a week for 4 weeks.
Time to First Reaching a Hughes Functional Grade (FG) Score <=1
The mobility of the participants was evaluated on a 7 point disability functional grade scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 metre (m) across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. The Kaplan-Meier estimate of time to event of FG\<=1 is reported. Time (days) to first event=Date of first event-Date of first dose+1. Participants who discontinued early without achieving FG \<= 1 were censored at the date of discontinuation. Participants who completed the study without achieving FG\<=1 were censored at the date of study completion.
Time frame: Up to Week 24
Number of Participants With A Hughes Functional Grade (FG) Score <=1
The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. If a participant had an FG score \<= 1 prior to or at Week 8 and Week 24, respectively, then the participant is considered a responder. Otherwise, participants discontinued prior to Week 8 and Week 24 or with an FG score \> 1 at Week 8 and Week 24 are nonresponders, respectively.
Time frame: Week 8, Week 24
Number of Participants With A Hughes Functional Grade Score Improvement of >=3
The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. Participants with a change from baseline in FG score (value at Week 24 - baseline value) \<= -3 were considered a responder. Participants with change from baseline \> -3 and participants who discontinued prior to Week 24 were considered non-responders.
Time frame: Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as an adverse event (AE) with onset on or after the first dose of the study drug. An AE is any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Week 24
Free Complement Component 5 in Serum
Time frame: Week 24
Hemolytic Complement Activity in Serum
Time frame: Week 24
Length of Stay in the Hospital
For participants with multiple hospitalizations, the total duration of all hospitalizations was summarized.
Time frame: Up to Week 24
Number of Participants Who Required Mechanical Ventilator Support
For participants with more than 1 episode of the same support, the total duration across all episodes was summarized.
Time frame: Up to Week 24
Concentration of Eculizumab in Serum
Time frame: Up to Week 24
Number of Participants With Positive Antidrug Antibodies
Time frame: Up to Week 12
| Milestone | Eculizumab | Placebo |
|---|---|---|
| Started | 37 | 20 |
| Received at least 1 dose of study drug | 37 | 20 |
| Completed | 32 | 18 |
| Not completed | 5 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Physician decision | 1 | 1 |
The mobility of the participants was evaluated on a 7 point disability functional grade scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 metre (m) across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. The Kaplan-Meier estimate of time to event of FG\<=1 is reported. Time (days) to first event=Date of first event-Date of first dose+1. Participants who discontinued early without achieving FG \<= 1 were censored at the date of discontinuation. Participants who completed the study without achieving FG\<=1 were censored at the date of study completion.
| Days | Eculizumab | Placebo |
|---|---|---|
| Time to First Reaching a Hughes Functional Grade (FG) Score <=1 | 112.0 (59.0 to NA) | 168.0 (36.0 to NA) |
The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. If a participant had an FG score \<= 1 prior to or at Week 8 and Week 24, respectively, then the participant is considered a responder. Otherwise, participants discontinued prior to Week 8 and Week 24 or with an FG score \> 1 at Week 8 and Week 24 are nonresponders, respectively.
| Participants | Eculizumab | Placebo |
|---|---|---|
| Week 8 | 12 | 7 |
| Week 24 | 20 | 13 |
The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. Participants with a change from baseline in FG score (value at Week 24 - baseline value) \<= -3 were considered a responder. Participants with change from baseline \> -3 and participants who discontinued prior to Week 24 were considered non-responders.
| Participants | Eculizumab | Placebo |
|---|---|---|
| Number of Participants With A Hughes Functional Grade Score Improvement of >=3 | 16 | 10 |
TEAEs were defined as an adverse event (AE) with onset on or after the first dose of the study drug. An AE is any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Eculizumab | Placebo |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 34 | 19 |
| micrograms/milliliters | Eculizumab | Placebo |
|---|---|---|
| Free Complement Component 5 in Serum | 131.0438 ± 29.40068 | 147.8833 ± 36.70182 |
| percentage of hemolysis | Eculizumab | Placebo |
|---|---|---|
| Hemolytic Complement Activity in Serum | 91.79 ± 11.077 | 91.83 ± 11.767 |
For participants with multiple hospitalizations, the total duration of all hospitalizations was summarized.
| days | Eculizumab | Placebo |
|---|---|---|
| Length of Stay in the Hospital | 49.5 ± 27.15 | 39.8 ± 12.97 |
For participants with more than 1 episode of the same support, the total duration across all episodes was summarized.
| Participants | Eculizumab | Placebo |
|---|---|---|
| Number of Participants Who Required Mechanical Ventilator Support | 8 | 1 |
| micrograms/milliliters | Eculizumab |
|---|---|
| Concentration of Eculizumab in Serum | 4.690 ± 0.0000 |
| Participants | Eculizumab | Placebo |
|---|---|---|
| Number of Participants With Positive Antidrug Antibodies | 0 | 0 |
Collected over Day 1 up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 1/37 (2.7%) | 4/37 (10.8%) | 34/37 (91.9%) |
| Placebo | 0/20 (0%) | 1/20 (5%) | 18/20 (90%) |
| Event | Eculizumab | Placebo |
|---|---|---|
| Pneumonia aspirationInfections and infestations | 2/37 | 0/20 |
| Chronic inflammatory demyelinating polyradiculoneuropathyNervous system disorders | 0/37 | 1/20 |
| HangingGeneral disorders | 1/37 | 0/20 |
| COVID-19Infections and infestations | 1/37 | 0/20 |
| Event | Eculizumab | Placebo |
|---|---|---|
| InsomniaPsychiatric disorders | 10/37 | 8/20 |
| ConstipationGastrointestinal disorders | 4/37 | 7/20 |
| Urinary tract infectionInfections and infestations | 5/37 | 3/20 |
| Aspartate aminotransferase increasedInvestigations | 2/37 | 3/20 |
| Alanine aminotransferase increasedInvestigations | 1/37 | 3/20 |
| HyponatraemiaMetabolism and nutrition disorders | 0/37 | 3/20 |
| HeadacheNervous system disorders | 5/37 | 3/20 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 3/37 | 3/20 |
| DiarrhoeaGastrointestinal disorders | 5/37 | 1/20 |
| PyrexiaGeneral disorders | 5/37 | 0/20 |
Full analysis set included all randomized participants who received at least 1 dose of study drug and had a baseline functional grade (FG) score and at least 1 postbaseline FG score.
| Age, Continuous(years) | Eculizumab | Placebo | Total |
|---|---|---|---|
| Mean | 56.6 ± 19.61 | 56.2 ± 18.34 | 56.4 ± 19.01 |
| Sex: Female, Male(Participants) | Eculizumab | Placebo | Total |
|---|---|---|---|
| Female | 19 | 5 | 24 |
| Male | 18 | 15 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Eculizumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 37 | 20 | 57 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Eculizumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 37 | 20 | 57 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Aug 2022, 16 months.
Results were first posted in Feb 2024, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →